- Home
- KFII vs TBPH Comparison
KFII vs TBPH Comparison
Compare KFII & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KFII
- TBPH
- Stock Information
- Founded
- KFII 2024
- TBPH 2013
- Country
- KFII United States
- TBPH United States
- Employees
- KFII N/A
- TBPH N/A
- Industry
- KFII
- TBPH Biotechnology: Pharmaceutical Preparations
- Sector
- KFII
- TBPH Health Care
- Exchange
- KFII NYSE
- TBPH Nasdaq
- Market Cap
- KFII 393.3M
- TBPH 464.5M
- IPO Year
- KFII 2025
- TBPH N/A
- Fundamental
- Price
- KFII $10.08
- TBPH $8.98
- Analyst Decision
- KFII
- TBPH Buy
- Analyst Count
- KFII 0
- TBPH 3
- Target Price
- KFII N/A
- TBPH $11.33
- AVG Volume (30 Days)
- KFII 103.4K
- TBPH 253.4K
- Earning Date
- KFII 01-01-0001
- TBPH 05-08-2025
- Dividend Yield
- KFII N/A
- TBPH N/A
- EPS Growth
- KFII N/A
- TBPH N/A
- EPS
- KFII N/A
- TBPH N/A
- Revenue
- KFII N/A
- TBPH $65,266,000.00
- Revenue This Year
- KFII N/A
- TBPH $51.09
- Revenue Next Year
- KFII N/A
- TBPH N/A
- P/E Ratio
- KFII N/A
- TBPH N/A
- Revenue Growth
- KFII N/A
- TBPH 6.11
- 52 Week Low
- KFII $9.90
- TBPH $7.44
- 52 Week High
- KFII $10.09
- TBPH $10.90
- Technical
- Relative Strength Index (RSI)
- KFII N/A
- TBPH 41.09
- Support Level
- KFII N/A
- TBPH $9.90
- Resistance Level
- KFII N/A
- TBPH $10.55
- Average True Range (ATR)
- KFII 0.00
- TBPH 0.36
- MACD
- KFII 0.00
- TBPH -0.02
- Stochastic Oscillator
- KFII 0.00
- TBPH 15.82
About KFII K&F GROWTH ACQUISITION CORP II
K&F Growth Acquisition Corp II is a special purpose acquisition company.
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).